Weighted Average Number of Shares Outstanding, Basic of G1 Therapeutics, Inc. from 31 Dec 2020 to 30 Jun 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
G1 Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2020 to 30 Jun 2024.
  • G1 Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Jun 2024 was 52,475,190, a 1.6% increase year-over-year.
  • G1 Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 51,733,487, a 19% increase from 2022.
  • G1 Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 43,626,113, a 4% increase from 2021.
  • G1 Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2021 was 41,943,417, a 11% increase from 2020.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

G1 Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 52,475,190 +808,091 +1.6% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 52,171,684 +523,750 +1% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2024 2024 Q1
Q4 2023 51,733,487 +5,453,679 +12% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q3 2023 51,777,731 +8,978,389 +21% 01 Jul 2023 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 51,667,099 +8,959,396 +21% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 51,647,934 +8,960,733 +21% 01 Jan 2023 31 Mar 2023 10-Q 01 May 2024 2024 Q1
Q4 2022 46,279,808 +3,735,487 +8.8% 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2023 2022 FY
Q3 2022 42,799,342 +415,769 +0.98% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 42,707,703 +587,853 +1.4% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 42,687,201 +1,986,374 +4.9% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 42,544,321 01 Oct 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 42,383,573 01 Jul 2021 30 Sep 2021 10-K 01 Mar 2023 2022 FY
Q2 2021 42,119,850 01 Apr 2021 30 Jun 2021 10-K 01 Mar 2023 2022 FY
Q1 2021 40,700,827 01 Jan 2021 31 Mar 2021 10-K 01 Mar 2023 2022 FY

G1 Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 51,733,487 +8,107,374 +19% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 43,626,113 +1,682,696 +4% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 41,943,417 +4,065,391 +11% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 37,878,026 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.